Within the past 20 years, the field of precision medicine has been transformed. For biotech companies, this new landscape holds tremendous promise for innovation. So, why aren’t more companies leveraging this approach? In this episode, Parexel precision medicine experts Angela Qu and Arlene Hughes join host Alberto Grignolo to discuss this conundrum, and what biotechs should be thinking about right from the start, to open up the opportunity for this approach to help bring innovation and new therapies to more patients.  

Ver todos los episodios